IRVINE, Calif., Jan. 26, 2009 (GLOBE NEWSWIRE) -- SenoRx, Inc. (Nasdaq:SENO) today announced that it has further extended its international reach to encompass five additional global markets. In addition to the 24 countries where SenoRx products are already being sold internationally, the company will begin marketing EnCor(r), its vacuum-assisted breast biopsy product, and its GelMark(tm) line of breast biopsy tissue markers through distributors in Egypt, Greece, Poland, Saudi Arabia, Thailand, Turkey and the United Arab Emirates.
SenoRx is partnering with local in-country distributors who have breast imaging and/or interventional radiology franchises in select markets. SenoRx has previously established partnering relationships with distributors in Australia, Austria, Belgium, Denmark, Finland, France, Germany, Hong Kong, Iceland, Ireland, Italy, Luxembourg, Mexico, The Netherlands, Norway, Portugal, Russia, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan and the United Kingdom.
"SenoRx continues to expand its international footprint in key markets where breast-care is increasingly becoming a national healthcare priority," said Lloyd Malchow, SenoRx President and Chief Executive Officer. "We have had positive results with our earlier international expansion initiatives and continue to see attractive opportunities for growth in the global marketplace. With the addition of these seven new geographic markets, SenoRx will now have a presence in more than 30 countries outside North America."
EnCor and SenoRx breast tissue biopsy markers have previously received the necessary regulatory clearances in countries within the European Economic Community and in all of the other countries that SenoRx has established distribution channels.
About SenoRx
SenoRx (Nasdaq:SENO) develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis and treatment of breast cancer, including its EnCor(r) vacuum-assisted breast biopsy system and Contura(tm) MLB catheter for delivering radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer. SenoRx's field sales organization serves over 1,000 breast diagnostic and treatment centers in the United States and Canada. In addition, SenoRx sells several of its products through distribution partners in more than 30 countries outside the U.S. and Canada. The company's line of breast care products includes biopsy disposables, biopsy capital equipment, diagnostic adjunct products and therapeutic disposables. SenoRx is developing additional minimally invasive products for the diagnosis and treatment of breast cancer. For more information, visit the company's website at www.senorx.com.
The SenoRx, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3605
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning international sales growth are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause SenoRx's actual results to differ materially from the statements contained herein. Information on potential risk factors that could affect SenoRx's business and its financial results are detailed in its most recent quarterly report on Form 10-Q, as filed with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. SenoRx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events